cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Allakos Inc
7 own
12 watching
Current Price
$4.85
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
419.82M
52-Week High
52-Week High
8.73
52-Week Low
52-Week Low
2.535
Average Volume
Average Volume
0.43M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization419.82M
icon52-Week High8.73
icon52-Week Low2.535
iconAverage Volume0.43M
iconDividend Yield--
iconP/E Ratio--
What does the Allakos Inc do?
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company s lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
Read More
How much money does Allakos Inc make?
News & Events about Allakos Inc.
Zolmax
3 months ago
Cantor Fitzgerald reiterated their overweight rating on shares of Allakos (NASDAQ:ALLK Get Rating) in a report published on Tuesday , Benzinga reports. Cantor Fitzgerald currently has a $7.00 target price on the stock. ALLK has been the subject of a number of other reports. Piper Jaffray Companies ...
Ticker Report
3 months ago
Piper Sandler assumed coverage on shares of Allakos (NASDAQ:ALLK Get Rating) in a report released on Tuesday, Marketbeat.com reports. The brokerage issued an overweight rating and a $22.00 target price on the stock. A number of other equities research analysts have also recently commented on...
Zolmax
3 months ago
Research analysts at Piper Sandler initiated coverage on shares of Allakos (NASDAQ:ALLK Get Rating) in a report released on Tuesday, MarketBeat reports. The brokerage set an overweight rating and a $22.00 price target on the stock. Piper Sandlers target price indicates a potential upside of 260.07% ...
Zolmax
6 months ago
Allakos Inc. (NASDAQ:ALLK Get Rating) Equities researchers at Jefferies Financial Group lifted their FY2022 EPS estimates for Allakos in a note issued to investors on Monday, November 7th. Jefferies Financial Group analyst M. Raycroft now expects that the company will post earnings per share of ($5....
Globe Newswire
7 months ago
Siglec-10 is a myeloid checkpoint receptor selectively expressed on tumor associated macrophages and dendritic cells AK007 potently blocks all known ligand interaction with Siglec-10, including the dont eat me signal CD24 Monotherapy treatment with a Siglec-10 antagonist antibody polarized tumor-...
Frequently Asked Questions
Frequently Asked Questions
What is Allakos Inc share price today?
plus_minus_icon
Can Indians buy Allakos Inc shares?
plus_minus_icon
How can I buy Allakos Inc shares from India?
plus_minus_icon
Can Fractional shares of Allakos Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Allakos Inc stocks?
plus_minus_icon
What is today’s traded volume of Allakos Inc?
plus_minus_icon
What is today’s market capitalisation of Allakos Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Allakos Inc?
plus_minus_icon
What percentage is Allakos Inc down from its 52-Week High?
plus_minus_icon
What percentage is Allakos Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$4.85
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
SCHOLAR ROCK HOLDING CORP
SCHOLAR ROCK HOLDING CORP
$6.94
$0.18 (2.66 %)
PHATHOM PHARMACEUTICALS INC
PHATHOM PHARMACEUTICALS INC
$12.30
$0.55 (4.68 %)
CABALETTA BIO INC
CABALETTA BIO INC
$12.34
$0.56 (4.75 %)
Chemomab Therapeutics Ltd
Chemomab Therapeutics Ltd
$1.75
$0.05 (2.94 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
SCHOLAR ROCK HOLDING CORP
SCHOLAR ROCK HOLDING CORP
$6.94
$0.18 (2.66 %)
PHATHOM PHARMACEUTICALS INC
PHATHOM PHARMACEUTICALS INC
$12.30
$0.55 (4.68 %)
CABALETTA BIO INC
CABALETTA BIO INC
$12.34
$0.56 (4.75 %)
Chemomab Therapeutics Ltd
Chemomab Therapeutics Ltd
$1.75
$0.05 (2.94 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00